1. < Cedars Sinai DoM

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Related Posts

Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis

Kao KD, Troost JP, Yang JD, Salgia R, Woolen SA, Mehta N, Hoteit MA, Jalal PK, El Dahan KS, Daher D, Quirk L, Patel N,[...]

Latency of Hypertensive Disorders of Pregnancy and Cardiovascular Risk 2-7 Years After Delivery

Shree S, Pike M, Yee LM, Levine L, Simhan H, Silver RM, Greenland P, Saade G, Bairey Merz CN, Chung J, Cleary EM, Grobman W,[...]

Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall survival risk stratification after transarterial chemoembolization in hepatocellular carcinoma

Wang C, He Y, Wang Y, Deng Z, Wang L, Li D. Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall[...]